Why is Tilray Brands (TLRY) Stock Sinking Despite Market Gains

Key Takeaways

• Tilray Brands (TLRY) stock has significantly underperformed the broader market, currently trading at $7.75, a steep decline from its $23.20 52-week high, largely due to sector volatility and "buy the rumor, sell the news" reactions to U.S. cannabis reclassification hopes.
• Despite reporting its second-highest adjusted EBITDA of $27.6 million in Q4 FY2025 and strategic diversification into beverages and wellness, Tilray faces substantial profitability challenges, evidenced by a -252.6% TTM net margin and a $1.3969 billion non-cash impairment charge.
• While analyst consensus is a "Hold" with a median price target of $10.00, the company's high short interest, negative free cash flow, and dependence on future U.S. federal legalization create a high-risk, high-reward profile for investors.

Why is Tilray Brands (TLRY) Stock Sinking Despite Market Gains?

Tilray Brands (TLRY) has seen its stock price plummet, trading at $7.75 as of February 20, 2026, a stark contrast to broader market uptrends. This decline represents a significant drop from its 52-week high of $23.20, highlighting persistent investor skepticism and sector-specific headwinds. The cannabis industry remains highly volatile, and Tilray, a prominent player, has been particularly susceptible to these swings.

A major factor contributing to recent price weakness was a classic "buy the rumor, sell the news" event surrounding potential U.S. federal cannabis reclassification. Reports in late 2025 suggested the U.S. administration was considering moving marijuana from a Schedule I to a Schedule III substance. This news initially sent TLRY shares soaring by roughly 75% over five trading days, including a 27% jump in a single session.

However, once the U.S. government officially moved to reschedule cannabis, the stock quickly gave back those gains. Shares fell 5.2% on December 17, 2025, and another 9% on December 19, 2025, as investors took profits and the reality set in that reclassification, while beneficial, is not full federal legalization. This pattern underscores the speculative nature of cannabis stocks and their sensitivity to regulatory headlines.

Furthermore, the company executed a 1:10 reverse stock split on December 2, 2025, a move often undertaken by companies to boost their share price and maintain Nasdaq listing compliance. While technically neutral, reverse splits can sometimes be perceived negatively by the market, signaling underlying struggles rather than fundamental strength. This context of a declining stock price, coupled with a reverse split, paints a picture of a company fighting against significant market pressures.

What Do Tilray's Latest Financials Reveal About Its Health?

Tilray's most recent financial disclosures paint a mixed picture, showcasing strategic moves towards diversification alongside significant profitability challenges. For the fourth quarter of fiscal year 2025 (ended May 31, 2025), the company reported net revenue of $224.5 million, a 2% year-over-year decrease, missing the consensus estimate of $233.3 million. While adjusted EPS came in at a positive $0.02, beating estimates, the GAAP diluted EPS was a staggering -$1.30, primarily due to a massive $1.3969 billion non-cash impairment charge related to its 2021 Aphria acquisition.

Looking at the trailing twelve months (TTM), Tilray's financial health indicators reveal deep-seated issues. The company reported a TTM net margin of -252.6% and an operating margin of -266.0%, indicating that its core operations are far from profitable. Returns on equity, assets, and invested capital are all deeply negative, at -114.1%, -100.6%, and -112.4% respectively, reflecting substantial value destruction for shareholders.

Despite these struggles, there are glimmers of operational improvement. Tilray achieved its second-highest ever quarterly consolidated adjusted EBITDA of $27.6 million in Q4 FY2025, and management projects FY2026 adjusted EBITDA to be between $62 million and $72 million. The company also reported $821.3 million in revenue for fiscal year 2025, a 4.1% increase year-over-year, though it fell short of its own revised guidance of $850-$900 million. This miss was attributed to beverage volume softness, SKU rationalization, and export permit delays.

Tilray's balance sheet shows some resilience, with a current ratio of 2.81 (TTM) and $256 million in cash and marketable securities as of Q4 FY2025. The debt-to-equity ratio stands at a manageable 0.20 (TTM). However, free cash flow remains deeply negative at -$127.5 million for FY2025, a -112.0% decrease year-over-year, suggesting that despite cash on hand, the business is not generating sufficient cash from its operations to fund its investments.

What Strategic Moves is Tilray Making to Navigate the Market?

Tilray Brands is actively pursuing a multi-pronged strategy to diversify its revenue streams and reduce its reliance on the volatile cannabis market. The company is positioning itself as a global consumer packaged goods (CPG) entity, expanding into beverages and wellness products. This diversification is critical given the slow pace of cannabis legalization and intense competition in its core market.

A significant recent development is the exclusive multi-year U.S. brewing and commercial partnership with the Carlsberg Group, announced on February 18, 2026. This collaboration is a strategic move to bolster Tilray's beverage segment, which already saw 19% revenue growth in FY2025, reaching $241 million. The partnership aims to leverage Carlsberg's extensive distribution network and brewing expertise, potentially expanding Tilray's reach in the non-alcoholic beer and other beverage categories.

In the cannabis sector, Tilray is focusing on international expansion, particularly in Europe and emerging markets like the Middle East, India, Türkiye, and Asia. International cannabis revenue increased by 19% in fiscal 2025, with Q4 alone seeing a 71% surge. The company is also enhancing its global supply chain and increasing cultivation footprint to meet growing demand. This international push is crucial, as global cannabis gross margin expanded by 700 basis points in fiscal 2025, indicating better profitability abroad compared to the highly competitive Canadian market.

Tilray is also exploring the integration of AI across its global operations to enhance efficiency and drive growth. This includes using advanced horticulture automation technology in greenhouses, combined with AI-driven data insights, to optimize conditions, increase output, and reduce costs. Such technological investments, while modest at $284K in R&D for FY2025, could be vital for long-term operational improvements and cost savings in a capital-intensive industry.

What Do Analysts Say, and What Are the Key Risks?

Wall Street analysts currently hold a "Hold" consensus rating for Tilray Brands, based on 20 analyst ratings (4 Buy, 14 Hold, 2 Sell). This lukewarm sentiment reflects the company's challenging financial performance despite its strategic efforts. The consensus price target stands at $8.00, with a median of $10.00, suggesting a modest upside from the current $7.75 share price. However, the range is wide, from a low of $2.00 to a high of $10.00, indicating significant divergence in expert opinions.

A major risk factor for Tilray is its high short interest, which recently increased by 4.5% to 15.85 million shares, representing 13.71% of its float. This elevated short interest, higher than the peer average of 11.96%, signals a strong bearish sentiment among a segment of investors who believe the stock will continue to decline. A high number of days to cover short positions, approximately 4.18 days, further suggests that short sellers are entrenched.

Operationally, Tilray faces continued profitability challenges. The TTM net income was a staggering -$2.2 billion for FY2025, a -792.6% decrease year-over-year, and EPS was -$2.46, down -645.5%. While much of this is due to non-cash impairment charges, the underlying business is still struggling to generate consistent profits. The company's negative free cash flow of -$127.5 million (FY2025) is another red flag, indicating that it's burning cash rather than generating it.

The cannabis industry itself remains fraught with regulatory uncertainty, particularly in the U.S. While reclassification to Schedule III would offer benefits like reduced taxes and improved banking access, it does not equate to full federal legalization. Tilray's long-term growth hinges significantly on broader U.S. policy shifts, which are notoriously unpredictable. Oversupply in the Canadian market and intense price compression also continue to hamper its core cannabis segment.

Is Tilray Brands a Dip-Buying Opportunity or a Value Trap?

For investors considering Tilray Brands, the current valuation presents a classic high-risk, high-reward scenario. The stock is trading significantly below its 52-week high and analyst median price target, which might suggest a dip-buying opportunity for those bullish on the long-term cannabis thesis. The company's strategic diversification into beverages and wellness, coupled with international expansion, offers potential avenues for future growth beyond its core Canadian cannabis market.

However, the deep profitability issues, evidenced by persistent net losses and negative free cash flow, cannot be ignored. The massive non-cash impairment charge in Q4 FY2025 highlights past overvaluations and the ongoing struggle to generate sustainable earnings. While adjusted EBITDA shows some positive trends, it's crucial to distinguish between adjusted metrics and GAAP profitability, which remains elusive.

The stock's extreme volatility and high short interest further underscore the speculative nature of an investment in Tilray. While U.S. cannabis reclassification could provide a tailwind, the "buy the rumor, sell the news" phenomenon has already played out, and the path to full federal legalization remains long and uncertain. Investors must weigh the potential for significant upside from a favorable regulatory environment against the very real risks of continued operational losses and market skepticism.

Ultimately, Tilray is not for the faint of heart. It requires a strong conviction in the future of global cannabis and the company's ability to execute its diversification strategy effectively. For those with a high-risk tolerance and a long-term horizon, the current price might be an attractive entry point, but it's essential to understand that this is a bet on future potential rather than current financial strength.

Tilray Brands remains a speculative play, heavily reliant on a favorable shift in U.S. federal cannabis policy and successful execution of its global diversification strategy. Investors should brace for continued volatility and prioritize a long-term perspective, understanding that profitability remains a significant hurdle.

Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.